Saturday 17 October 2026
Export SIBN’s income statement to Excel — free account
SiBone
SIBN Healthcare Medical Devices
SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 15.2%, EPS grew 35.7%, free cash flow grew 60.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
19.68
0.23
−1.16%
Follow SIBN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.40 | 2.69 | 4.22 | 3.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
934.19 | (235.06) | 490.26 | 272.27 | |
P/B ratio |
3.98 | 3.10 | 4.77 | 3.69 | |
Price to Tangible BV |
3.98 | 3.10 | 4.77 | 3.69 | |
EV/Sales |
2.89 | 2.17 | 3.66 | 2.72 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
249.00 | 238.84 | (1,090.93) | (430.20) | |
EV/FCF |
(140.64) | (80.72) | (81.02) | (49.64) | |
Quick Ratio |
7.37 | 8.17 | 7.03 | 6.52 | |
Current Ratio |
9.15 | 9.99 | 8.55 | 7.97 | |
Net Debt/EBITDA |
30.53 | 27.20 | 79.78 | 24.13 | |
Debt/Assets |
14.32% | 14.67% | 14.91% | 15.17% | |
Debt/Equity |
0.20 | 0.20 | 0.20 | 0.21 | |
Asset Turnover |
0.89 | 0.88 | 0.86 | 0.84 | |
Operating CF/Net income |
(0.19) | 0.55 | (1.05) | (0.51) | |
Capex/Depreciation |
(1.30) | (1.00) | (1.22) | (3.63) | |
Interest Coverage |
(8.04) | (8.60) | (3.91) | (8.03) | |
Research and Development Expense of Revenue |
9.32% | 7.97% | 7.74% | 8.72% | |
Selling, General and Administrative Expense of Revenue |
78.79% | 81.47% | 75.66% | 82.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
10.67% | 11.46% | 10.61% | 12.80% | |
Graham Net Nets |
0.21 | 0.27 | 0.18 | 0.23 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.08%) | (3.09%) | (2.23%) | (3.46%) | |
Free Cash Flow Yield |
(0.60%) | (1.00%) | (1.07%) | (1.67%) | |
Revenue per Share |
1.26 | 1.20 | 1.31 | 1.13 | |
Operating CF per Share |
0.02 | (0.05) | 0.04 | 0.05 | |
Capex per Share |
(0.03) | (0.02) | (0.03) | (0.07) | |
Free Cash Flow per Share |
(0.02) | (0.08) | 0.01 | (0.01) | |
Cash per Share |
3.28 | 3.29 | 3.44 | 3.37 | |
Shareholders Equity per Share |
4.10 | 4.07 | 4.13 | 3.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.10 | 4.07 | 4.13 | 3.99 | |
Free Cash Flow |
(0.77) | (3.44) | 0.44 | (0.62) | |
Working Capital |
195.87 | 193.23 | 190.84 | 184.34 | |
Capital Expenditures |
(1.54) | (1.08) | (1.29) | (2.95) | |
Net Current Asset Value |
153.50 | 150.94 | 155.09 | 148.64 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.78 | 28.83 | 28.69 | 25.72 | |
Average Payables |
8.02 | 7.23 | 5.56 | 7.52 | |
Average Inventory |
36.32 | 32.96 | 30.49 | 30.62 | |
Average Assets |
239.84 | 235.00 | 234.50 | 230.64 | |
Average Common Equity |
176.35 | 173.10 | 172.25 | 168.55 |
Columns are period end dates